Appointment of Shore Capital as Joint Broker

RNS Number : 5818F

Oxford BioDynamics PLC

19 May 2017

 

19 May 2017

Oxford BioDynamics Plc

("OBD" or the "Company")

Appointment of Shore Capital as Joint Broker

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce the appointment of Shore Capital Stockbrokers Limited ("Shore Capital") as joint broker to the Company, with immediate effect.

For further details contact:

Oxford BioDynamics Plc		[phone]
Christian Hoyer Millar, CEO
Katie Long, CFO
Stifel Nicolaus Europe Limited		[phone]
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital		[phone]
Joint Broker
Bidhi Bhoma
Edward Mansfield
FTI Consulting		[phone]
Financial Public Relations Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

APPOKFDPNBKDBPD